BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 9639741)

  • 1. [Treatment and prognostic factors of epithelial ovarian cancer].
    Wei L; Qian H; Li W
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):476-9. PubMed ID: 9639741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytoreductive surgery plus combined chemotherapy for the treatment of advanced ovarian cancer].
    Li M; Huang X
    Zhonghua Fu Chan Ke Za Zhi; 1996 Oct; 31(10):621-3. PubMed ID: 9275460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
    Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
    Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of long-term prognostic factors of epithelial ovarian cancer].
    Li MD; Li YJ; Huang YW; Huang H
    Ai Zheng; 2004 Nov; 23(11):1306-10. PubMed ID: 15522179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognosis and prognostic factor analysis epithelial ovarian cancer].
    Wen H; Sun W; Guo Y
    Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):159-62. PubMed ID: 9596891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Recurrent epithelial ovarian cancer].
    Ding X; Lang J; Shen K
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):30-2. PubMed ID: 11263170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies of second-look operations (SLO) in ovarian cancer].
    Yuzawa H
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
    Zhao XD; Zhang Q; Zhang Y
    Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic factors of common epithelial ovarian cancer treated by surgery and cisplatin based combination chemotherapy].
    Sasaki H; Ochiai K; Terashima Y; Mochizuki S; Soda T; Nishimura H; Yakushiji M; Hirabayashi M
    Gan No Rinsho; 1989 Oct; 35(13):1615-20. PubMed ID: 2585733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multidisciplinary treatment of recurrent epithelial ovarian carcinoma and prognostic analysis].
    Huang X; Cai SM; Tang J; Li ZT; Zang RY
    Zhonghua Fu Chan Ke Za Zhi; 2004 Sep; 39(9):602-5. PubMed ID: 15498187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An analysis of factors influential in improving the survival rate of patients with ovarian cancer].
    Ohta M; Tomoda Y; Kano T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1008-15. PubMed ID: 2730004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The clinical and pathological characteristics of epithelial ovarian carcinoma in patients with age under 40].
    Wen H; Sun W; Guo Y
    Zhonghua Fu Chan Ke Za Zhi; 1997 Sep; 32(9):548-51. PubMed ID: 9639757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical analysis of prognostic factors for stage III ovarian epithelial carcinoma].
    Wu M; Shen K; Lang JH; Huang RL; Huang HF; Pan LY
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(20):1406-9. PubMed ID: 16029654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological characteristics of hereditary ovarian cancer syndrome].
    Zhong Y; Sheng XG; Ma ZF; Ma YB; Liu NF; Chen YT; Gao R; Wang YY; Sun L
    Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):676-80. PubMed ID: 20079180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.